share_log

Vertex Pharmaceuticals | SC TO-T/A: Third party tender offer statement (Amendment)

Vertex Pharmaceuticals | SC TO-T/A: Third party tender offer statement (Amendment)

福泰製藥 | SC TO-T/A：發行招標公告
美股SEC公告 ·  05/20 08:30
Moomoo AI 已提取核心訊息
Vertex Pharmaceuticals Incorporated successfully completed the acquisition of Alpine Immune Sciences, Inc. through its wholly owned subsidiary, Adams Merger Sub, Inc. The tender offer, which was set at a purchase price of $65.00 per share, concluded at one minute past 11:59 p.m. Eastern Time on May 17, 2024, with approximately 87% of Alpine's issued and outstanding shares being validly tendered and not properly withdrawn. This satisfied the Minimum Tender Condition of the offer. On May 18, 2024, Adams Merger Sub, Inc. accepted for payment all shares tendered by the expiration time, in line with the Merger Agreement. The final step of the acquisition was completed on May 20, 2024, when Adams Merger Sub, Inc. merged with and into Alpine, making Alpine a wholly owned subsidiary of Vertex. Following the merger, Alpine's shares were delisted from Nasdaq and deregistered under the Exchange Act.
Vertex Pharmaceuticals Incorporated successfully completed the acquisition of Alpine Immune Sciences, Inc. through its wholly owned subsidiary, Adams Merger Sub, Inc. The tender offer, which was set at a purchase price of $65.00 per share, concluded at one minute past 11:59 p.m. Eastern Time on May 17, 2024, with approximately 87% of Alpine's issued and outstanding shares being validly tendered and not properly withdrawn. This satisfied the Minimum Tender Condition of the offer. On May 18, 2024, Adams Merger Sub, Inc. accepted for payment all shares tendered by the expiration time, in line with the Merger Agreement. The final step of the acquisition was completed on May 20, 2024, when Adams Merger Sub, Inc. merged with and into Alpine, making Alpine a wholly owned subsidiary of Vertex. Following the merger, Alpine's shares were delisted from Nasdaq and deregistered under the Exchange Act.
Vertex Pharmicals Incorporated通過其全資子公司Adams Merger Sub, Inc.成功完成了對Alpine Immune Sciences, Inc.的收購。該要約定爲每股65.00美元，於美國東部時間2024年5月17日晚上11點59分後一分鐘結束，阿爾派約87％的已發行和流通股票進行了有效投標，未正確撤回。這滿足了報價的最低投標條件。2024年5月18日，Adams Merger Sub, Inc. 根據合併協議，接受了在到期前投標的所有股票的支付。收購的最後一步於2024年5月20日完成，當時Adams Merger Sub, Inc.與阿爾派合併併入阿爾派，使阿爾派成爲Vertex的全資子公司。合併後，阿爾派的股票從納斯達克退市，並根據《交易法》註銷了註冊。
Vertex Pharmicals Incorporated通過其全資子公司Adams Merger Sub, Inc.成功完成了對Alpine Immune Sciences, Inc.的收購。該要約定爲每股65.00美元，於美國東部時間2024年5月17日晚上11點59分後一分鐘結束，阿爾派約87％的已發行和流通股票進行了有效投標，未正確撤回。這滿足了報價的最低投標條件。2024年5月18日，Adams Merger Sub, Inc. 根據合併協議，接受了在到期前投標的所有股票的支付。收購的最後一步於2024年5月20日完成，當時Adams Merger Sub, Inc.與阿爾派合併併入阿爾派，使阿爾派成爲Vertex的全資子公司。合併後，阿爾派的股票從納斯達克退市，並根據《交易法》註銷了註冊。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息